The best weight loss pills for insulin resistance are not one-size-fits-all — the right option depends on your clinical profile, comorbidities, and individual circumstances. Insulin resistance disrupts the body's ability to regulate blood glucose effectively, making weight management more challenging and increasing the risk of type 2 diabetes and cardiovascular disease. In the UK, several licensed medicines — including metformin, GLP-1 receptor agonists such as semaglutide and liraglutide, orlistat, and tirzepatide — may be used as part of a broader treatment plan. This article outlines how these medicines work, what NICE and NHS guidance says, and how to access appropriate support safely.

How Insulin Resistance Affects Weight and Treatment Options

Insulin resistance occurs when the body's cells do not respond effectively to insulin, the hormone responsible for regulating blood glucose levels. As a result, the pancreas produces increasingly larger amounts of insulin to compensate, leading to elevated circulating insulin levels — a condition known as hyperinsulinaemia. This metabolic disruption can make weight loss more challenging for many people, particularly around the abdomen, and may mean that diet and exercise alone are insufficient for some individuals.

The relationship between insulin resistance and weight is bidirectional. Excess body fat — especially visceral fat stored around the organs — worsens insulin sensitivity, creating a cycle that can be difficult to break. Over time, untreated insulin resistance increases the risk of type 2 diabetes and cardiovascular disease, and is commonly associated with polycystic ovary syndrome (PCOS) and fatty liver disease (increasingly referred to as metabolic dysfunction-associated steatotic liver disease, or MASLD).

In routine NHS care, insulin resistance is typically assessed using cardiometabolic risk markers such as HbA1c, fasting glucose, and lipid profiles, rather than by directly measuring insulin levels.

Managing insulin resistance typically requires a multimodal approach, which may include:

• Dietary changes — reducing refined carbohydrates and ultra-processed foods

• Regular physical activity — particularly resistance and aerobic exercise

• Weight management — even modest weight loss of 5–10% of body weight can meaningfully improve insulin sensitivity

• Pharmacological support — where lifestyle measures alone are insufficient

It is important to understand that no single medication is universally considered the "best" option. Treatment must be tailored to the individual's clinical profile, comorbidities, and personal circumstances. Any pharmacological intervention should complement — not replace — sustainable lifestyle changes, and should always be initiated under medical supervision.

Medications Used for Weight Loss in Insulin Resistance

Several licensed medicines are used in the UK to support weight loss in people with insulin resistance, often as part of broader metabolic management. These are not "diet pills" in the traditional sense; rather, they are clinically evaluated medications with specific mechanisms of action.

Metformin is one of the most widely prescribed medicines for insulin resistance and type 2 diabetes. It works by reducing hepatic glucose production and improving peripheral insulin sensitivity. Metformin is not licensed specifically as a weight loss medicine, but it is associated with modest weight stabilisation. It is also used off-label in conditions such as PCOS to improve hormonal and metabolic parameters — this use is not covered by its UK marketing authorisation and should always be discussed with a GP or specialist.

GLP-1 receptor agonists represent a newer class of medicines that mimic the glucagon-like peptide-1 hormone. They work by:

• Slowing gastric emptying

• Reducing appetite and caloric intake

• Improving insulin secretion in a glucose-dependent manner

It is important to note that not all medicines in this class are licensed for weight management in the UK. Wegovy® (semaglutide 2.4 mg) and Saxenda® (liraglutide 3 mg) are specifically licensed for chronic weight management in adults with obesity or overweight with weight-related comorbidities. Ozempic® (semaglutide 1 mg or 2 mg) is licensed for the management of type 2 diabetes only and is not licensed for weight loss.

Orlistat is a lipase inhibitor that reduces dietary fat absorption by approximately 30%. Prescription orlistat 120 mg is initiated by a prescriber, whilst orlistat 60 mg (Alli®) is available over the counter for adults with a BMI of ≥28 kg/m² when used alongside a reduced-calorie, lower-fat diet. It remains one of the few medicines with a long-standing licence for weight management in the UK.

Tirzepatide (Mounjaro®) is a dual GIP and GLP-1 receptor agonist that has received MHRA approval for the management of type 2 diabetes. Its use for obesity and weight management is subject to ongoing NICE technology appraisal and NHS commissioning processes; patients should check current NHS guidance for the latest position on access. Clinical trial data — including the SURMOUNT programme — demonstrated substantial average weight reductions in participants, many of whom had insulin resistance.

What the Evidence Says: NICE and NHS Guidance

NICE (the National Institute for Health and Care Excellence) provides clear guidance on the pharmacological management of obesity and type 2 diabetes, both of which are closely linked to insulin resistance. NICE CG189 (Obesity: identification, assessment and management) recommends that drug treatment should only be considered alongside dietary, physical activity, and behavioural interventions — not as a standalone solution. NICE NG28 (Type 2 diabetes in adults: management) provides separate guidance relevant to people with insulin resistance who have progressed to type 2 diabetes.

For orlistat, NICE CG189 recommends it be prescribed only when the patient has made meaningful lifestyle changes and meets specific BMI thresholds (BMI ≥30 kg/m², or ≥28 kg/m² with weight-related comorbidities). Treatment should be reviewed after 12 weeks, and continued only if the patient has lost at least 5% of their initial body weight.

For semaglutide 2.4 mg (Wegovy®), NICE has recommended its use within specialist weight management services for adults with a BMI of ≥35 kg/m² and at least one weight-related comorbidity, or a BMI of 30–34.9 kg/m² in certain high-risk groups. NICE specifies a maximum treatment duration of two years under current commissioning criteria. Access is through NHS specialist (tier 3) weight management services, and availability remains phased.

For liraglutide 3 mg (Saxenda®), NICE has recommended its use under narrower criteria — specifically for adults with pre-diabetes and a high risk of cardiovascular disease, within specialist weight management services. Eligibility criteria are more restricted than for Wegovy®.

NICE guidance also advises that BMI thresholds should be applied at a level approximately 2.5 kg/m² lower for people from some minority ethnic backgrounds, who may be at equivalent cardiometabolic risk at a lower BMI.

For tirzepatide (Mounjaro®), MHRA approval currently covers type 2 diabetes management. A NICE technology appraisal for the weight management indication is ongoing; patients and clinicians should refer to the latest NICE and NHS England guidance for the current commissioning position. Patients should be aware that access through the NHS may differ from private prescribing routes.

Eligibility, Safety, and Who These Medicines Are Suitable For

Eligibility for weight loss medicines in the context of insulin resistance depends on several clinical factors, and not everyone will be suitable for every treatment. A thorough medical assessment is essential before any pharmacological intervention is initiated.

Eligibility criteria vary by medicine and are defined by both the product's UK marketing authorisation and NICE commissioning guidance:

• Orlistat 120 mg: BMI ≥30 kg/m², or ≥28 kg/m² with weight-related risk factors, following meaningful lifestyle change

• Wegovy® (semaglutide 2.4 mg): BMI ≥35 kg/m² with at least one comorbidity, or BMI 30–34.9 kg/m² in certain high-risk groups, within specialist weight management services (maximum 2 years)

• Saxenda® (liraglutide 3 mg): pre-diabetes with high cardiovascular risk, within specialist services, under NICE TA criteria

• Ethnicity-adjusted BMI thresholds (approximately 2.5 kg/m² lower) apply for some minority ethnic groups across these criteria

All prescribing decisions should follow the relevant UK product SmPC and applicable NICE technology appraisals. Private prescribing should adhere to the same safety standards as NHS prescribing.

Metformin is generally well tolerated and widely used, but is contraindicated in people with significant renal impairment (eGFR <30 mL/min/1.73 m²). The dose should be reviewed if eGFR falls to 30–45 mL/min/1.73 m². It should be used cautiously in those with hepatic disease or other risk factors for lactic acidosis (see side effects section). Its use in PCOS is off-label in the UK and should be discussed with a GP or endocrinologist.

GLP-1 receptor agonists should not be used in individuals with:

• A history of pancreatitis

• Severe gastrointestinal disease or gastroparesis

• Pregnancy or breastfeeding (use is not recommended; effective contraception should be used during treatment)

• Other contraindications or precautions as detailed in the individual product SmPC (available via the electronic Medicines Compendium, emc)

Patients with pre-existing diabetic retinopathy who are prescribed GLP-1 receptor agonists should be aware that rapid improvement in blood glucose control may be associated with a temporary worsening of retinopathy; this should be discussed with the prescribing clinician.

Orlistat is generally considered safe for long-term use but is not appropriate for those with chronic malabsorption syndromes or cholestasis.

Any individual considering these medicines should have their full clinical picture reviewed, including all current medications, to identify potential interactions.

Potential Side Effects and Important Precautions

All medicines carry the potential for side effects, and weight loss medications are no exception. Understanding these risks helps patients make informed decisions and recognise when to seek medical advice.

Metformin commonly causes gastrointestinal side effects, particularly when first initiated, including:

• Nausea, diarrhoea, and abdominal discomfort

• These effects are often dose-dependent and can be minimised by taking the medicine with food or using a modified-release formulation

• Long-term use may reduce vitamin B12 absorption in some patients. The MHRA advises that B12 levels should be checked if symptoms such as anaemia or peripheral neuropathy develop, or if risk factors for deficiency are present; periodic monitoring may be appropriate in those at risk

• Rarely, metformin is associated with lactic acidosis, a serious metabolic complication. Patients should seek urgent medical attention if they experience severe malaise, muscle pain, difficulty breathing, abdominal pain, or feel very unwell, particularly if they are unwell with vomiting, diarrhoea, or dehydration

GLP-1 receptor agonists are associated with a range of gastrointestinal effects, most commonly nausea, vomiting, and constipation, particularly during dose escalation. These effects tend to diminish over time. More serious but rare adverse effects include:

• Pancreatitis — patients should seek urgent medical attention if they experience severe, persistent abdominal pain

• Gallbladder disease — including gallstones, which may be more likely with rapid weight loss

• Dehydration and acute kidney injury — persistent vomiting or diarrhoea can lead to dehydration; patients should maintain adequate fluid intake and seek advice if gastrointestinal symptoms are prolonged

• Diabetic retinopathy complications — people with diabetes and pre-existing retinopathy should discuss monitoring with their clinician before starting treatment

• Injection site reactions (for injectable formulations)

Orlistat works locally in the gut and is not systemically absorbed, but it can cause oily or fatty stools, faecal urgency, and flatulence — particularly if dietary fat intake remains high. It may also reduce the absorption of fat-soluble vitamins (A, D, E, and K), so a daily multivitamin taken at a different time of day is often recommended.

Patients taking any of these medicines should be advised to contact their GP promptly if they experience:

• Unexplained or severe abdominal pain

• Signs of hypoglycaemia (particularly if also taking other diabetes medications)

• Significant mood changes or thoughts of self-harm

• Symptoms of dehydration or any new or worsening symptoms that concern them

Reporting side effects: Suspected adverse reactions to any medicine can be reported directly to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. Reporting helps the MHRA monitor the ongoing safety of medicines used in the UK.

Speaking to Your GP or Specialist About Your Options

If you are living with insulin resistance and are finding it difficult to manage your weight through lifestyle changes alone, speaking to your GP is an important first step. A GP can assess your full medical history, arrange relevant investigations — such as fasting glucose, HbA1c, lipid profile, renal function (eGFR), liver function tests, blood pressure, and waist circumference — and determine whether pharmacological support is appropriate for your situation.

It is worth approaching this conversation with realistic expectations. Weight loss medicines are tools to support a broader management plan, not quick fixes. The most effective outcomes are consistently seen when medication is combined with sustained dietary changes, increased physical activity, and behavioural support. Your GP may refer you to a specialist weight management service (sometimes called a tier 3 service), a dietitian, or an endocrinologist depending on the complexity of your needs. Access to GLP-1 receptor agonists for weight management on the NHS is currently through these specialist services, in line with NICE technology appraisal criteria.

Questions worth raising with your GP or specialist include:

• Am I eligible for any weight management medicines on the NHS?

• Would metformin be appropriate given my insulin resistance?

• Are there any specialist services or structured weight management programmes I can be referred to?

• How will my progress be monitored, and what are the review criteria?

It is also important to be cautious about purchasing weight loss products online or through unregulated channels. Some products marketed as "weight loss pills" for insulin resistance are not licensed medicines and may carry significant safety risks. The MHRA regularly issues warnings about unlicensed and counterfeit products circulating online. Always ensure that any prescribed medicine is dispensed by a pharmacy registered with the General Pharmaceutical Council (GPhC), and that your prescriber is appropriately qualified and regulated by the GMC, NMC, or GPhC as appropriate.

With the right support and a personalised treatment plan, meaningful and sustainable improvements in both weight and insulin sensitivity are achievable.

Frequently Asked Questions